The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥480.67Fair value¥2,578.58Bull¥3,111.06
FairClose
52-week traded range
52W low ¥5,080.0052W high ¥6,117.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
KOBAYASHI PHARMACEUTICAL CO.,LTD. closed at ¥5,768.00, 123.7% above the consensus fair value of ¥2,578.58 drawn from 9 valuation models.
Financial DNA score 43/100 — Average. P/E of 117.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥3,111.06
-46.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥1,769.00
-69.3%
√(22.5 × EPS × BVPS)
EPS=49.19, BVPS=2827.45 · outside Graham range (P/E 117.3, P/B 2) — asset-light, treat as a rough floor
P/E Fair Value
¥983.80
-82.9%
EPS × 20x (sector P/E)
EPS=49.19, Sector P/E=20x
Peter Lynch (PEG)
¥1,475.70
-74.4%
EPS × Growth% (PEG = 1 is fair)
EPS=49.19, g=30%
EV/EBITDA
¥2,997.41
-48.0%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=22.28B
Dividend Discount (DDM)
¥1,323.76
-77.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=103.82, r=10%, g=2%
Book Value (P/B)
¥480.67
-91.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=2827.45, ROE=1.7%, g=3%, r=10%
Reverse DCF
¥5,768.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 31.4% | Historical: -34.4%
Margin of Safety
¥1,465.97
-74.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1954.62, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.